BioCentury | Apr 21, 2020
Product Development

April 20 Quick Takes: Top-line data for BMS, Idorsia and Ascendis; plus Otsuka-Esperion, Regeneron and more

BMS combo meets in Phase III for malignant pleural mesothelioma Bristol Myers Squibb Co. (NYSE:BMY) said top-line results from the Phase III CheckMate -743 trial showed a combination of anti-PD-1 mAb Opdivo nivolumab and anti-CTLA4...
BioCentury | Jul 31, 2019
Financial News

Alizé seeks to build out company with largest European A round this year

French biotech Alizé Pharma 3 is taking a more ambitious approach than its predecessors, and now has a €67 million ($74.5 million) series A round to fund two endocrine programs through Phase II testing and...
BioCentury | Aug 4, 2017
Company News

Express Scripts releases 2018 formulary exclusions

Express Scripts Holding Co. (NASDAQ:ESRX) posted a list of drugs it will not cover in its 2018 National Preferred Formulary, along with preferred alternatives in each drug category. The new formulary excluded 64 additional drugs...
BioCentury | Jul 31, 2017
Company News

Radius Health scores with Express Scripts 2018 formulary

Radius Health Inc. (NASDAQ:RDUS) gained $1.90 to $44.03 Monday after Express Scripts Holding Co. (NASDAQ:ESRX) listed Radius' osteoporosis drug Tymlos abaloparatide-SC as a preferred alternative to Forteo teriparatide from Eli Lilly and Co. (NYSE:LLY). The...
BioCentury | May 5, 2017
Clinical News

FDA approves Tymlos for osteoporosis

FDA approved an NDA from Radius Health Inc. (NASDAQ:RDUS) for Tymlos abaloparatide-SC (BA058-SC, ITM-058) to treat postmenopausal women with osteoporosis at high risk for fracture. The company expects to launch the drug in May. EMA...
BioCentury | Apr 28, 2017
Clinical News

Natpar parathyroid hormone regulatory update

The European Commission granted conditional approval to Natpar parathyroid hormone from Shire as an adjunct treatment for adults with chronic hypoparathyroidism that cannot be adequately controlled on standard calcium and vitamin D treatment. The company...
BioCentury | Mar 16, 2017
Targets & Mechanisms

Bone appétit!

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...
BioCentury | Mar 14, 2017
Clinical News

Abaloparatide-SC regulatory update

FDA extended by 3 months the PDUFA date for abaloparatide-SC to treat postmenopausal osteoporosis. The new PDUFA date is June 30. Radius said FDA is reviewing information the company submitted in response to the agency’s...
BioCentury | Mar 10, 2017
Company News

FDA extends review of Radius' osteoporosis candidate

Radius Health Inc. (NASDAQ:RDUS) slipped $2.26 to $40.85 on Friday after it said FDA delayed by three months the PDUFA date for abaloparatide-SC (BA058-SC), which it is reviewing to treat postmenopausal osteoporosis. The new PDUFA...
BioCentury | Mar 2, 2017
Clinical News

Natpar regulatory update

EMA's CHMP recommended conditional approval of Natpar parathyroid hormone from Shire as an adjunct treatment for adults with chronic hypoparathyroidism that cannot be adequately controlled on standard calcium and vitamin D treatment. To gain full...
Items per page:
1 - 10 of 604